GHIT Request for Proposals: Drug Discovery and Development Process (GHIT-RFP-HTLP-2025-001)

The Global Health Innovative Technology Fund (GHIT Fund) announces the Request for Proposals (RFP) for the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates on malaria, tuberculosis, Chagas disease , and visceral Leishmaniasis. 

The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.

Eligibility criteria:

• Compounds orginally/derived from Japan.
• Novel hit structures confirmed.
• Primary results validated on hit compounds (>90% pure).
• Acceptable in vitro concentration-response curves.
• Preliminary SAR with existing analogues.
• Progressable chemotypes .
• >10-fold selectivity for cytotoxicity using a mammalian cell line (e.g. HepG2).
• Adequate selectivity in counter assay(s).
• No blocking intellectual property (IP).
• No major synthesis or formulation issues anticipated.

Read here for more information.

Intent to Apply deadline January 10, 2025. No latter than 10:00am Tokio time.